Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | PTPRB | P23467 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2641869 | 0.84 | ENPP2 (0.45) | SMN1; SMN2CYP2C19PTPN1ALDH1A1MAPT | |
| SCHEMBL12082470 | 0.80 | CCNT1 (0.40) | MMP2MMP3MMP9MMP14ALDH1A1 | |
| SCHEMBL3589633 | 0.77 | NQO1 (0.50) | MMP2MMP3MMP9MMP14MAPT | |
| SCHEMBL14341660 | 0.74 | APP (0.47) | SMN1; SMN2APPNPC1POLBRAB9A | |
| SCHEMBL2127451 | 0.74 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP2C19ALDH1A1MAPTNPC1 | |
| SCHEMBL7866228 | 0.73 | FFAR1 (0.40) | MMP2MMP3MMP9MMP14SMN1; SMN2 | |
| SCHEMBL7855924 | 0.72 | APP (0.37) | MMP2MMP3MMP9MMP14SMN1; SMN2 | |
| SCHEMBL6160052 | 0.72 | FYN (0.47) | MMP2MMP3MMP9MMP14SMN1; SMN2 | |
| SCHEMBL15143758 | 0.72 | MAOB (0.58) | MAOB | |
| SCHEMBL28879120 | 0.72 | APP (0.37) | MMP2MMP3MMP9MMP14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796668-B2 | Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use | REATA PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160145200-A1 | NATURAL PRODUCT ANALOGS INCLUDING AN ANTI-INFLAMMATORY CYANOENONE PHARMACORE AND METHODS OF USE | REATA PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | US | disclosed |
| US-9233998-B2 | Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use | REATA PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20120283450-A1 | COMPOUNDS INCLUDING AN ANTI-INFLAMMATORY PHARMACORE AND METHODS OF USE | REATA PHARMACEUTICALS, INC. | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145200-A1 | NATURAL PRODUCT ANALOGS INCLUDING AN ANTI-INFLAMMATORY CYANOENONE PHARMACORE AND METHODS OF USE | PTGES, LTB4R, LTB4R2 | MMP2 1379/4885MMP3 857/4885MMP9 852/4885 |
| US-20120283450-A1 | COMPOUNDS INCLUDING AN ANTI-INFLAMMATORY PHARMACORE AND METHODS OF USE | PTGES, PTGS1, PTGES2 | MMP2 740/4885MMP3 359/4885MMP9 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.